The Filing Desk

Viatris vs Zoetis

Viatris VTRS · Zoetis ZTS · Pharmaceuticals

Viatris reported revenue of $14.3 billion in fiscal 2025, 1.5 times Zoetis' $9.5 billion in fiscal 2025. Viatris' revenue fell 3.0% in its latest year, and Zoetis' grew 2.3%. Free cash flow was $1.9 billion at Viatris and $2.3 billion at Zoetis.

Side by side

ViatrisZoetis
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$14.3B$9.5B
Revenue growth−3.0%2.3%
Revenue growth a year, last 5 years3.7%7.2%
Gross margin35.1%71.8%
Operating margin−18.6%—
Net margin−24.6%28.2%
Free cash flow$1.9B$2.3B
Free cash flow margin13.6%24.1%
Return on capital−7.0%29.3%
Net debt to EBITDA96.5x1.7x
Dividends and buybacks$500M$4.1B
Change in diluted share count−1.9%−2.4%
Last close$18.29$80.97
P/E at the last close—13.3×
Insider trades, last 12 monthsbought $2,222, sold $1.1 millionbought $886,384, sold $2.5 million
Piotroski F-score4 of 98 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ViatrisZoetis
Operating margin
Percent of revenue
ViatrisZoetis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ViatrisZoetis

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Viatris and Zoetis pages.